

BE

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
18 July 2002 (18.07.2002)

PCT

(10) International Publication Number
WO 02/055481 A1(51) International Patent Classification²: **C07C 229/50**,
233/60, A61K 31/195, A61P 25/00(21) International Application Number: **PCT/US01/45866**(22) International Filing Date:
14 December 2001 (14.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

01500007.8	11 January 2001 (11.01.2001)	EP
01500206.6	2 August 2001 (02.08.2001)	EP
60/329,786	16 October 2001 (16.10.2001)	US
01500263.7	7 November 2001 (07.11.2001)	EP

(71) Applicant (for all designated States except US): **ELI LILLY AND COMPANY** [US/US], Lilly Corporate Center, Indianapolis, IN 46285 (US).

(72) Inventors: and

(75) Inventors/Applicants (for US only): **BUENO MELENDO**, Ana, Belen [ES/ES]; Lilly, S. A., Avenida de la Industria 30, E-28100 Alcobendas (ES). **COFFEY**, David, Scott [US/US]; 6246 Tennison Way, Indianapolis, IN 46236 (US). **DANTZIG**, Anne, Hollins [US/US]; 18 Twin Oaks, Crawfordsville, IN 47933 (US). **DE DIOS**, Alfonso [ES/ES]; Lilly, S. A., Avenida de la Industria 30, E-28100 Alcobendas (ES). **DOMINGUEZ-FERNANDEZ**, Carmen [ES/ES]; Lilly, S. A., Avenida de la Industria 30, E-28100 Alcobendas (ES). **HERIN**, Marc [BE/BE]; Lilly MSG Development Centre S. A., Parc Scientifique de Louvain-la-Neuve, B-1348 Mont-Sai Rue Granbompre, 11 (BE). **HILLGREN**, Kathleen, Michele [US/US]; 5752 Brockton Court, #4, Indianapolis, IN 46220 (US). **MARTIN**, Jose, Alfredo [ES/ES]; Lilly, S. A., Avenida de la Industria 30, E-28100 Alcobendas (ES).


MARTIN-CABREJAS, Luisa, Maria [ES/ES]; Lilly, S. A., Avenida de la Industria 30, E-28100 Alcobendas (ES). **MARTINEZ-GRAU**, Maria, Angeles [ES/ES]; Lilly, S. A., Avenida de la Industria 30, E-28100 Alcobendas (ES). **MASSEY**, Steven, Marc [US/US]; 3525 Waterstone Court, Indianapolis, IN 46268 (US). **MOHER**, Eric, David [US/US]; 4524 Pepper Court, Indianapolis, IN 46237 (US). **MONN**, James, Allen [US/US]; 5718 Allenwood Court, Indianapolis, IN 46268 (US). **MONTERO SALGADO**, Carlos [ES/ES]; Lilly, S. A., Avenida de la Industria 30, E-28100 Alcobendas (ES). **PEDERSEN**, Steven, Wayne [US/US]; 3724 Ontario Circle, Indianapolis, IN 46268 (US). **PEDREGAL-TERCERO**, Concepcion [ES/ES]; Lilly, S. A., Avenida de la Industria 30, E-28100 Alcobendas (ES). **SWEETANA**, Stephanie, Ann [US/US]; 4112 Saratoga Drive, Bloomington, IN 47408 (US). **VALLI**, Matthew, John [US/US]; 812 Eaglewood Drive, Zionsville, IN 46077 (US).

(74) Agents: **ANDERSON**, Arvie, J. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EC, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: **PRODRUGS OF EXCITATORY AMINO ACIDS**

(57) Abstract: This invention relates to synthetic excitatory amino acid prodrugs according to formula (I) and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.

WO 02/055481 A1

**Declaration under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW; ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY,

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Published:

- with international search report
— entirely in electronic form (except for this front page) and available upon request from the International Bureau

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Prodrugs of Excitatory Amino Acids

This invention relates to synthetic excitatory amino acid prodrugs (and their pharmaceutically acceptable salts) and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.


Treatment of neurological or psychiatric disorders, such as anxiety disorder, have been linked to selective activation of metabotropic excitatory amino acid receptors such as (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid, also known as LY354740, which is disclosed in U.S. Patent No. 5,750,566 (the '566 patent) issued May 12, 1998 is an active MGLUR2 receptor agonist, CNS Drug Reviews, 5, pgs. 1-12 (1999).

The present invention provides for a prodrug form of LY354740, which enhances the in vivo potency of LY354740, producing higher oral exposure of the parent compound. In addition, when compounds of the present invention are administered, no circulating level of prodrug was detected with high in vitro bioconversion to the parent molecule. Further, the peptide prodrugs are stable under all ranges of pH and are nontoxic. Compounds of the present invention represent the best approach for maintaining LY354740-like safety and efficacy in humans with increased oral bioavailability. Preclinical studies with, (1S,2S,5R,6S)-2-[(2'S)-(2'-Amino)-propionyl]amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid hydrochloride, the compound of the present invention, has shown greatly enhanced oral potency in the treatment of anxiety without the attendant problems of

toxicity, instability at desired pH ranges and low in vivo conversion.

Accordingly, the present invention provides a compound of formula I

5



wherein

R¹³, R¹⁴ and R¹⁷ are hydrogen;

10

or a pharmaceutically acceptable salt thereof.

Compounds of the invention have been found to be useful prodrugs for LY354740 a selective agonist of metabotropic glutamate receptors and are therefore useful in the pharmaceutical treatment of diseases of the central nervous system such as neurological diseases, for example neurodegenerative diseases, and as antipsychotic, anxiolytic, drug-withdrawal, antidepressant, anticonvulsant, analgesic and anti-emetic agents.

20

It will be appreciated that the compounds of formula (I) contain at least four asymmetric carbon atoms, three being in the cyclopropane ring and one being at the α -carbon of the amino acid group. Accordingly, the compounds of the invention may exist in and be isolated in enantiomerically pure form, in racemic form, or in a diastereoisomeric mixture.

25

The amino acid moiety preferably has the natural amino acid configuration, i.e. the L-configuration relative to D-glycerol aldehyde.

The present invention includes pharmaceutically acceptable salts of the compound of formula I. These salts can exist in conjunction with the acidic or basic portion of the molecule and can exist as acid addition, primary, secondary, tertiary, or quaternary ammonium, alkali metal, or alkaline earth metal salts. Generally, the acid addition salts are prepared by the reaction of an acid with a compound of formula I. The alkali metal and alkaline earth metal salts are generally prepared by the reaction of the hydroxide form of the desired metal salt with a compound of formula I.

Some particular salts provide certain formulation advantages due to their crystalline form. Non-crystalline forms of compounds may be amorphous and hygroscopic. Crystalline forms of pharmaceutical compounds are sometimes more desirable because they are not amorphous.

A particular pharmaceutically acceptable salt of the peptide of formula I is (1S,2S,5R,6S)-2-[(2'S)-(2'-Amino)-propionyl]amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid hydrochloride salt.

Another particular pharmaceutically acceptable salt of the peptide of formula I is (1S,2S,5R,6S)-2-[(2'S)-(2'-Amino)-propionyl]amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid methane sulfonate salt.

Acids commonly employed to form such salts include inorganic acids, for example hydrochloric, hydrobromic, nitric, sulphuric or phosphoric acids, or with organic acids, such as organic carboxylic acids, for example, glycollic, maleic, hydroxymaleic, fumaric, malic, tartaric,

citric, salicyclic, o-acetoxybenzoic, or organic sulphonic, 2-hydroxyethane sulphonic, toluene-p-sulphonic, methane-sulfonic or naphthalene-2-sulphonic acid.

In addition to pharmaceutically-acceptable salts, other
5 salts are included in the invention. They may serve as intermediates in the purification of compounds or in the preparation of other, for example pharmaceutically-acceptable, acid addition salts, or are useful for identification, characterization or purification.

10 A variety of physiological functions have been shown to be subject to influence by excessive or inappropriate stimulation of excitatory amino acid transmission. The formula I compounds of the present invention are believed to have the ability to treat a variety of neurological
15 disorders in mammals associated with this condition, including acute neurological disorder such as cerebral deficits subsequent to cardiac bypass surgery and grafting, stroke, cerebral ischemia, spinal cord trauma, head trauma, perinatal hypoxia, cardiac arrest, and hypoglycemic neuronal
20 damage. The formula I compounds are believed to have the ability to treat a variety of chronic neurological disorders, such as Alzheimer's disease, Huntington's Chorea, amyotrophic lateral sclerosis, AIDS-induced dementia, ocular damage and retinopathy, cognitive disorders, and idiopathic
25 and drug-induced Parkinson's. The present invention also provides methods for treating these disorders which comprises administering to a patient in need thereof an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.

30 The formula I compounds of the present invention treat a variety of other neurological disorders in patients that are associated with glutamate dysfunction, including

muscular spasms, convulsions, migraine headaches, urinary incontinence, pain, premenstrual dysphoric disorder (PDD), psychosis, (such as schizophrenia), drug tolerance and withdrawal (such as nicotine, opiates and benzodiazepines),
5 anxiety and related disorders, emesis, brain edema, chronic pain, and tardive dyskinesia. The formula I compounds are also useful as antidepressant and analgesic agents. Therefore, the present invention also provides methods for treating these disorders which comprise administering to a
10 patient in need thereof an effective amount of the compound of formula I, or a pharmaceutically acceptable salt thereof.

A compound of Formula I may be made by a process which is analogous to one known in the chemical art for the production of structurally analogous heterocyclic compounds
15 or by a novel process described herein. Such processes and intermediates useful for the manufacture of a compound of Formula I as defined above are provided as further features of the invention and are illustrated by the following procedures in which, unless otherwise specified, the
20 meanings of the generic radicals are as defined above.


(A) For a compound of formula I in which R^{13} , R^{14} , and R^{17} are hydrogen (a di-acid), deprotecting the amine group of a compound of formula I

where R^{17} is tert-butoxy carbonyl or a nitrogen
25 protecting group, with an acid as described in the General Procedures for Examples 3 and 4.

(B) For a compound of formula I in which R^{13} and R^{14} are both hydrogen (a di-acid), deprotecting a compound of formula I where R^{13} and R^{14} are not both hydrogen as
30 described in Scheme 2.


-6-

(C) For a compound of formula I in which R^{13} and R^{14} are not both hydrogen, amidating a compound of formula II



5


with a corresponding amino acid of formula III.



10 in which p is 0 or any integer from 1-10 and R^{17} is tert-butoxy carbonyl or a nitrogen-protecting group as described in the General Procedure for Example 1.

(D) For a compound of formula II where R^{13} and R^{14} are not hydrogen, where R^{13} and R^{14} may be a carboxy-protecting ester group (a di-ester), esterifying a compound of formula
15 II where R^{13} and R^{14} are both hydrogen (a di-acid).

(E) For a compound of formula II in which R^{13} and R^{14} are not hydrogen (a di-ester), deprotecting a compound of formula IV



20

where R^m is a nitrogen protecting group, as described in Preparation 2.

(F) For a compound of formula II where R^{13} and R^{14} are not both hydrogen (a di-ester), esterifying a compound of formula IV, as described in Preparation 2.

(G) For a compound of formula IV where R^{13} and R^{14} are both hydrogen (a di-acid), protecting the amine group of a compound of formula II as described in Preparation 1.

The term "nitrogen protecting group," as used herein, refers to those groups intended to protect or block the nitrogen group against undesirable reactions during synthetic procedures. Choice of the suitable nitrogen protecting group used will depend upon the conditions that will be employed in subsequent reaction steps wherein protection is required, as is well within the knowledge of one of ordinary skill in the art. Commonly used nitrogen protecting groups are disclosed in T.W. Greene and P.G.M. Wuts, Protective Groups In Organic Synthesis, 2nd Ed. (John Wiley & Sons, New York (1991)).

The term "carboxy-protecting group" as used herein refers to one of the ester derivatives of the carboxylic acid group commonly employed to block or protect the carboxylic acid group while reactions are carried out on other functional groups of the compound. Particular values include, for example, methyl, ethyl, tert-butyl, benzyl, methoxymethyl, trimethylsilyl, and the like. Further examples of such groups may be found in T.W. Greene and P.G.M. Wuts, Protecting Groups in Organic Synthesis, 3rd Ed. (John Wiley & Sons, N.Y. (1999)). The ester is decomposed by using a conventional procedure which does not affect another portion of the molecule.

Whereafter, for any of the above procedures, when a pharmaceutically acceptable salt of a compound of Formula I is required, it is obtained by reacting the acid of Formula

I with a physiologically acceptable base or by reacting a basic compound of Formula I with a physiologically acceptable acid or by any other conventional procedure.

The term "C₁-C₁₀ alkyl" represents a straight,
5 branched, or cyclic alkyl chain having from one to ten carbon atoms.

The term "C₂-C₁₀ alkenyl" represents straight or branched unsaturated alkyl chains having from two to ten carbon atoms, and having one or more carbon-carbon
10 double bond, such as, dienes and trienes. This group also includes both E and Z isomers.

The term "aryl" represents groups such as phenyl, substituted phenyl, and naphthyl. The term "arylalkyl" represents a C₁-C₄ alkyl group bearing one or more aryl
15 groups.

The term "affecting" refers to a formula I compound acting as an agonist at an excitatory amino acid receptor. The term "excitatory amino acid receptor" refers to a metabotropic glutamate receptor,
20 a receptor that is coupled to cellular effectors via GTP-binding proteins. The term "cAMP-linked metabotropic glutamate receptor" refers to a metabotropic receptor that is coupled to inhibition of adenylate cyclase activity.

25 The term "neurological disorder" refers to both acute and chronic neurodegenerative conditions, including cerebral deficits subsequent to cardiac bypass surgery and grafting, cerebral ischemia (for example stroke resulting from cardiac arrest), spinal
30 cord trauma, head trauma, Alzheimer's Disease, Huntington's Chorea, amyotrophic lateral sclerosis, AIDS-induced dementia, perinatal hypoxia, hypoglycemic

neuronal damage, ocular damage and retinopathy, cognitive disorders, idiopathic and drug-induced Parkinson's Disease. This term also includes other neurological conditions that are caused by glutamate
5 dysfunction, including muscular spasms, migraine headaches, urinary incontinence, drug tolerance, withdrawal, and cessation (i.e. opiates, benzodiazepines, nicotine, cocaine, or ethanol), smoking cessation, emesis, brain edema, chronic pain,
10 sleep disorders, convulsions, Tourette's syndrome, attention deficit disorder, and tardive dyskinesia.

The term "psychiatric disorder" refers to both acute and chronic psychiatric conditions, including schizophrenia, anxiety and related disorders (e.g.
15 panic attack and stress-related cardiovascular disorders), depression, bipolar disorders, psychosis, and obsessive compulsive disorders.

A particular aspect of the present invention includes a method for affecting the cAMP-linked
20 metabotropic glutamate receptors in a patient, which comprises administering to a patient requiring modulated excitatory amino acid neurotransmission a pharmaceutically-effective amount of a compound of formula I.

25 Another particular aspect of the present invention includes a method of administering an effective amount of a compound of formula II, where R^{13} and R^{14} are both hydrogen (a di-acid), which comprises administering to a patient requiring modulated excitatory amino acid
30 neurotransmission a pharmaceutically effective amount of a compound of formula I.

Another particular aspect of the present invention includes a method for treating a psychiatric disorder in a patient which comprises administering to the patient in need of treatment thereof a
5 pharmaceutically-effective amount of a compound of formula I.

Another particular aspect of the present invention includes a method for treating a neurological disorder in a patient which comprises administering to the
10 patient in need of treatment thereof a pharmaceutically-effective amount of a compound of formula I.

A preferred method for treating a psychiatric disorder in a patient comprises administering to the
15 patient in need thereof a pharmaceutically-effective amount of a compound of formula I wherein said psychiatric disorder is schizophrenia, anxiety and related disorders, depression, bipolar disorders, psychosis, and obsessive compulsive disorders.

20 A preferred method for treating a neurological disorder in a patient comprises administering to the patient in need thereof a pharmaceutically-effective amount of a compound of formula I wherein said neurological disorder is cerebral deficits subsequent
25 to cardiac bypass and grafting; cerebral ischemia; spinal cord trauma; head trauma; Alzheimer's Disease; Huntington's Chorea; amyotrophic lateral sclerosis; AIDS-induced dementia; perinatal hypoxia; hypoglycemic neuronal damage; ocular damage and retinopathy;
30 cognitive disorders; idiopathic and drug-induced Parkinsons' Disease; muscular spasms; migraine

-11-

headaches; urinary incontinence; drug tolerance,
withdrawal, and cessation; smoking cessation; emesis;
brain edema; chronic pain; sleep disorders;
convulsions; Tourette's syndrome; attention deficit
5 disorder; and tardive dyskinesia.

A more preferred method for treating a psychiatric
disorder in a patient comprises administering to the
patient in need thereof a pharmaceutically-effective
amount of a compound of formula I wherein said
10 psychiatric disorder is anxiety and related disorders.

A more preferred method for treating a
neurological disorder in a patient comprises
administering to the patient in need thereof a
pharmaceutically-effective amount of a compound of
15 formula I wherein said neurological disorder is drug
tolerance, withdrawal, and cessation; or smoking
cessation.

An additional aspect of the present invention is a
compound of formula I, or a pharmaceutically acceptable
20 salt thereof, for use as a pharmaceutical.

Another aspect of the present invention includes
the use of a compound of formula I, or a
pharmaceutically acceptable salt thereof, for the
manufacture of a medicament for treating neurological
25 or psychiatric disorders.

As used herein the term "effective amount" refers
to the amount or dose of the compound, upon single or
multiple dose administration to the patient, which
provides the desired effect in the patient under
30 diagnosis or treatment.

An effective amount can be readily determined by the attending diagnostician, as one skilled in the art, by the use of known techniques and by observing results obtained under analogous circumstances. In determining
5 the effective amount or dose of compound administered, a number of factors are considered by the attending diagnostician, including, but not limited to: the species of mammal; its size, age, and general health; the specific disease involved; the degree of or
10 involvement or the severity of the disease; the response of the individual patient; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; the use of
15 concomitant medication; and other relevant circumstances. For example, a typical daily dose may contain from about 25 mg to about 300 mg of the active ingredient. The compounds can be administered by a variety of routes including oral, rectal, transdermal,
20 subcutaneous, intravenous, intramuscular, bucal or intranasal routes. Alternatively, the compound may be administered by continuous infusion.


As used herein the term "patient" refers to a mammal, such as a mouse, guinea pig, rat, dog or human.
25 It is understood that the preferred patient is a human.

The term "treating" (or "treat") as used herein includes its generally accepted meaning which encompasses prohibiting, preventing, restraining, and slowing, stopping, or reversing progression of a
30 resultant symptom. As such, the methods of this invention encompass both therapeutic and prophylactic administration.

If not commercially available, the necessary starting materials for the above procedures may be made by procedures which are selected from standard techniques of organic and heterocyclic chemistry, techniques which analogous to the syntheses of known, structurally similar compounds, and the procedures described in the Examples, including novel procedures.

A further aspect of the present invention provides for a method of administering an effective amount of a compound of formula II, where R^{13} and R^{14} are both hydrogen (a di-acid), which comprises administering to a patient requiring modulated excitatory amino acid neurotransmission a pharmaceutically-effective amount of a compound of formula I.

Compounds of formula I are converted via enzymatic or hydrolytic process in vivo, to form compounds of formula II, where R^{13} and R^{14} are both hydrogen (a di-acid), as shown in Scheme 1 below.




Scheme 1: In Vivo Conversion

20

In particular, a crystalline form of a compound of formula I may be prepared according to the route outlined in Scheme 2 below in which each of R^{13} and R^{14} , respectively,

represents a value defined for the groups R^{13} and R^{14} . The process described in Scheme 2 is a synthesis method for the preparation of a crystalline hydrochloride salt form of a compound of formula I and a methanesulfonate salt form of a compound of formula I.



Scheme 2: Process for Preparation of Particular Salt

10

In scheme 2 above, the monohydrate of II, where R^{13} and R^{14} are both hydrogen (a di-acid), is treated with thionyl chloride and methanol affording the corresponding di-ester of II. Alternatively, catalytic hydrochloric acid may be used in place of thionylchloride. The di-ester, formula II,

15

is amidated with a compound of formula III using dicyclohexylcarbodiimide (DCC), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI) or isobutyl chloroformate as a coupling agent to afford a di-ester protected peptidyl compound of formula I. This transformation could also be achieved using the acid chloride or by using a variety of other peptide coupling reagents, for example, diphenyl chlorophosphate and 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT), bis(2-oxo-3-oxazolidinyl)phosphinic chloride and benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate.

The hydrolysis of the di-ester protected peptidyl compound of formula I with a suitable base such as lithium hydroxide or sodium hydroxide in THF affords the di-acid protected peptidyl compound of formula I, where R13 and R14 are both hydrogen (a di-acid). The di-acid protected peptidyl compound of formula I may be deprotected with a mineral or organic acid in a suitable solvent. Such conditions may produce the corresponding acid salt of the di-acid peptidyl compound of formula I as an amorphous solid or, directly, a crystalline solid. In the case of an amorphous solid, subsequent crystallization may occur from suitable solvents. For example, a di-acid protected peptidyl compound of formula I when treated hydrogen chloride gas in ethyl acetate provides the deprotected hydrochloride salt as an amorphous solid. The amorphous hydrochloride compound may then be crystallized from acetone and water to afford the crystalline hydrochloride salt compound of formula I. In the case of a crystalline solid which is formed directly, filtration of the reaction mixture may afford the crystalline salt. The zwitterionic compound of formula I is afforded by treatment of the crystalline

hydrochloride salt of formula I with sodium hydroxide. It will be appreciated by one of ordinary skill in the art that a compound of formula I may be prepared in one procedure where the indicated intermediates are not isolated.

5 The ability of compounds to modulate metabotropic glutamate receptor function may be demonstrated by examining their ability to influence either cAMP production (mGluR 2, 3, 4, 6, 7 or 8) or phosphoinositide hydrolysis (mGluR 1 or 5) in cells expressing these individual human metabotropic
10 glutamate receptor (mGluR) subtypes. (D. D. Schoepp, et al., *Neuropharmacol.*, 1996, 35, 1661-1672 and 1997, 36, 1-11).

 The ability of formula I compounds to treat anxiety or a related disorder may be demonstrated using the well known
15 fear potentiated startle and elevated plus maze models of anxiety described respectively in Davis, *Psychopharmacology*, 62:1;1979 and Lister, *Psychopharmacol*, 92:180-185; 1987

In Vitro Receptor Binding

20 To study the ability to affect receptor binding of compounds of the present invention in comparison to LY354740, displacement of a high affinity mGluR2 antagonist radioligand [³H]LY341495 to cell membranes from human mGluR2, human mGluR3, and native rat brain tissues was
25 determined. (See, Ornstein P. L., Arnold M. B., Bleisch T. J., Wright R. A., Wheeler W. J., and Schoepp D. D., [³H]LY341495, a highly potent, selective and novel radioligand for labeling group II metabotropic receptors. *Bioorg. Med. Chem. Lett.* 8: 1919-1922 (1998); and Johnson B.
30 G., Wright R. A., Arnold M. B., Wheeler W. J., Ornstein P. L., and Schoepp D. D., [³H]LY341495 as a novel rapid filtration antagonist radioligand for group II metabotropic

receptors: Characterization of binding to membranes of mGlu receptor subtype expressing cells. *Neuropharmacology* 38: 1519-1529 (1999))

As shown in Table 1 below, LY354740 displaced

- 5 [3H]LY341495 binding to rat forebrain membranes with a potency similar to that observed in human recombinant receptors. In contrast, the compound of formula I did not appreciably displace [3H]LY341495 binding to rat forebrain membranes at up to 10,000 nM.

10

Table 1. Comparison of receptor binding of compounds of the present invention with LY354740		
	Displacement of ³ H-LY341495 binding (K _i , nM) (mean±S.E., N=3)	
Receptor Preparation	<u>LY354740</u>	<u>Formula I</u>
Human mGluR2	84.7 ± 11.1	>10,000
Human mGluR3	125.6 ± 4.8	>10,000
Rat Forebrain	80.0 ± 7.3	>10,000

In Vivo Actions in Rat Fear Potentiated Startle Anxiety Model

- 15 To study the oral potencies of compounds of the present invention in comparison to LY354740 in an mGlu2/3 receptor linked therapeutic animal model, studies in the rat fear-potentiated startle assay were performed. This model was specifically chosen, as it is highly sensitive to mGlu2/3
- 20 agonists such as LY354740 and compounds of the present invention. (See, Helton D.R., Tizzano J.P., Monn J.A., Schoepp D.D., and Kallman M.J., Anxiolytic and side-effect profile of LY354740: A potent, high selective, orally active

-18-

agonist for group II metabotropic glutamate receptors, *J. Pharmacol. Exp. Ther.* 284: 651-660 (1998)). To verify that the actions of a compound of formula I in this model were mGlu2/3 receptor mediated, as has been shown previously for LY354740 (See, Tizzano, J.P., Griffey K.I., Ornstein P.L., Monn J.A., and Schoepp D.D., Actions of mGlu receptor agonists on fear-conditioning versus fear-expression in rats, *Neuropharmacology*, 38:A45 (#144) (1999)), the ability of LY341495 (an mGlu2/3 receptor antagonist) (See, Kingston A.E., Ornstein P.L., Wright R.A., Johnson B.G., Mayne N.G., Burnett J.P., Belagaje R., Wu S., and Schoepp D.D., LY341495 is a nanomolar potent and selective antagonist for group II metabotropic glutamate receptors, *Neuropharmacology*, 37: 1-12 (1998)) to block compound-mediated suppression of fear-potentiated startle was also determined. As a positive control in each experiment, diazepam (0.6 mg/kg i.p.) was used. All experiments were performed in fed rats.

In the fear potentiated startle model, animals are exposed to a neutral stimulus such as light (conditioned stimulus) with an aversive stimulus such as a shock (unconditioned stimulus). Following conditioning, when the animals are presented with a loud acoustic stimulus, larger startle responses are elicited when the startle stimulus is preceded by light.

Diazepam and buspirone hydrochloride, which are clinically proven anxiolytics, are effective at reducing the fear (increased startle response) associated with the presentation of light in the fear potentiated startle model, and in reducing the fear of open spaces in the elevated plus maze model.

Male Long Evans rats (180-400 g) or male NIH Swiss mice (18-35 g) were obtained from Harlan Sprague-

-19-

Dawley, Cumberland, IN, USA and acclimated at least 3 days before testing. Animals were housed at 23±2°C (relative humidity 30% to 70%) and given Purina Certified Rodent Chow and water ad libitum. The

5 photoperiod was 12 hours of light and 12 hours of dark, with dark onset at approximately 1800 hours.

Test compounds were dissolved in a vehicle of purified water and neutralized with 5 N NaOH to a pH of 7-8 when applicable. Diazepam (Sigma Chemical Company, 10 St. Louis, MO) was suspended in purified water by the dropwise addition of Tween 80. Control animals received the respective vehicle.

SL-LAB (San Diego Instruments, San Diego, CA) chambers were used for conditioning sessions and for 15 the production and recording of startle responses. A classical conditioning procedure was used to produce potentiation of startle responses. Briefly, on the first 2 days, rats were placed into dark startle chambers in which shock grids were installed.

20 Following a 5-minute acclimation period, each rat received a 1mA electric shock (500ms) preceded by a 5 second presentation of light (15 watt) which remained on for the duration of the shock. Ten presentations of the light and shock were given in each conditioning

25 session, rats were gavaged with a solution of test compound of water and startle testing sessions were conducted. A block of 10 consecutive presentations of acoustic startle stimuli (110 dB, non-light-paired) were presented at the beginning of the session in order

30 to minimize the influences of the initial rapid phase of habituation to the stimulus. This was followed by 20 alternating trials of the noise alone or noise

-20-

preceded by the light. Excluding the initial trial block, startle response amplitudes for each trial type (noise-alone vs. light+noise) were averaged for each rat across the entire test session.

5 As shown in the first row of Table 2, below, when given orally to fed rats, compounds of the present invention were active in the rat fear-potentiated startle test at 300 times lower doses when compared to LY354740. If this in vivo animal model data directly predicts human anxiety responses, 10 compounds of the present invention would produce anxiolytic effects in humans at 300 fold lower doses than the parent compound. Furthermore, the ability to produce a longer duration at lower doses when compared to parent may allow for once-a day dosing, as opposed to twice a day dosing.

15 In Vivo Exposure as Measured by Rat Plasma Concentration

To study the in vivo exposure of LY354740 following oral dosing of compounds of the present invention in comparison to LY354740, studies measuring the plasma concentrations of LY354740 in rats were performed.

20 Mature Fischer 344 male rats (190-270 gram) were obtained from Harlan Sprague-Dawley, Cumberland, IN, USA and acclimated in the study housing for 3 days. On day 4, test compounds were dissolved in buffered water (1mg/ml = test compound/20mM potassium dihydrogen phosphate, pH=2) and 25 given orally as a single 5mg/kg dose. Blood samples were collected through orbital sinus or cardiac puncture (last time point) at 0.5 and 1 hour or, alternatively, 1 and 3 hours. Plasma samples were stored at -20°C in the presence of phenylmethanesulfonyl fluoride, a protease inhibitor, 30 prior to analysis. Plasma samples and internal standard compounds were pretreated by solid phase extraction (SAX support, methanol/water/dilute acetic acid). As shown in

-21-

the second row of Table 2, below, the plasma concentrations (ng/ml) of LY354740 for each test compound were determined by LC/MS/MS and are presented as a sum of the concentrations at the 0.5 and 1 hour or, alternatively, 1 and 3 hour sample 5 time points.

Table 2. Comparison LY354740 and compounds of the present invention in the rat fear-potentiated startle assay		
	Compound	
Parameter Measured	LY354740	formula I
MED (1 hour pre-treatment)	3.0 mg/kg p.o.	0.01 mg/kg p.o.
Rat Exposure (ng/ml of LY354740 following 5 mg/kg p.o.)	466 ng/ml	7114 ng/ml

As shown above in Tables 1 and 2, in vitro studies show that the compounds of the present invention had no appreciable affinity *per se* for mGlu2/3 receptors. This indicates that the in vivo pharmacology of this compound in rats and humans would likely reflect the conversion of the prodrug to the parent molecule, LY354740, which then acts at mGlu2/3 receptors to produce a therapeutic effect. Further, in fact, when given orally to rats, the compounds of the current invention exhibit a 15 fold increase in plasma concentration of LY354740 when compared to LY354740. This demonstrates compounds of the present invention are converted to LY354740 *in vivo*.

The compounds of the present invention are preferably formulated prior to administration. Therefore, another aspect of the present invention is a pharmaceutical formulation comprising a compound of formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically-acceptable carrier, diluent, or excipient. The pharmaceutical formulations may be prepared by procedures well-known by one of ordinary skill in the art. In making the compositions of the present invention, the active ingredient will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier, and may be in the form of a capsule, sachet, paper, or other container. When the carrier serves as a diluent, it may be a solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active ingredient. The compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols, ointments containing, for example, up to 10% by weight of active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.

Some examples of suitable carriers, excipients, and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum, acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water syrup, methyl cellulose, methyl and propyl hydroxybenzoates, talc, magnesium stearate, and mineral oil. The formulations can additionally include lubricating agents, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents, or flavoring agents. Compositions of the invention may be formulated so as to

-24-

provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.

The compositions are preferably formulated in a unit dosage form, each dosage containing from about 5 mg to about 500 mg active ingredient, preferably about 25 mg to about 300 mg active ingredient. As used herein the term "active ingredient" refers to a compound included within the scope of formula I.

10 The term "unit dosage form" refers to a physically discrete unit suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable
15 pharmaceutical carrier, diluent, or excipient.

The following Examples further illustrate the compounds of the present invention and the methods for their synthesis. The Examples are not intended to be limiting to the scope of the invention in any respect, and should not be
20 so construed. All experiments were run under a positive pressure of dry nitrogen or argon. All solvents and reagents were purchased from commercial sources and used as received, unless otherwise indicated. Dry tetrahydrofuran (THF) was obtained by distillation from sodium or sodium
25 benzophenone ketyl prior to use. Proton nuclear magnetic resonance (^1H NMR) spectra were obtained on a Bruker Avance II bay-500 at 500 MHz, a Bruker Avance I bay-200 at 200MHz or a Varian Inova at 500 MHz. Electrospray mass spectroscopy (ESI) was performed on a Agilent MSD/B
30 intrument using acetonitrile/aqueous ammonium acetate as the mobile phase. Free atom bombardment mass spectroscopy (FABMS) was performed on a VG ZAB-2SE instrument. Field

desorption mass spectroscopy (FDMS) was performed using either a VG 70SE or a Varian MAT 731 instrument. Optical rotations were measured with a Perkin-Elmer 241 polarimeter. Chromatographic separation on a Waters Prep 500 LC was generally carried out using a linear gradient of the solvents indicated in the text. The reactions were generally monitored for completion using thin layer chromatography (TLC). Thin layer chromatography was performed using E. Merck Kieselgel 60 F254 plates, 5 cm X 10 cm, 0.25 mm thickness. Spots were detected using a combination of UV and chemical detection (plates dipped in a ceric ammonium molybdate solution [75 g of ammonium molybdate and 4 g of cerium (IV) sulfate in 500 mL of 10% aqueous sulfuric acid] and then heated on a hot plate). Flash chromatography was performed as described by Still, et al. Still, Kahn, and Mitra, *J. Org. Chem.*, 43, 2923 (1978). Elemental analyses for carbon, hydrogen, and nitrogen were determined on a Control Equipment Corporation 440 Elemental Analyzer, or were performed by the Universidad Complutense Analytical Centre (Facultad de Farmacia, Madrid, Spain). Melting points were determined in open glass capillaries on a Gallenkamp hot air bath melting point apparatus or a Büchi melting point apparatus, and are uncorrected.

The abbreviations, symbols and terms used in the examples have the following meanings.

Ac = acetyl
Anal. = elemental analysis
Bn or Bzl = benzyl
Bu = butyl
BOC = butoxycarbonyl
calcd = calculated
D₂O = deuterium oxide

-26-

DCC = dicyclohexylcarbodiimide
DIBAL-H = diisobutyl aluminum hydride
DMAP = dimethylaminopyridine
DMF = dimethylformamide
5 DMSO = dimethylsulfoxide
EDC = N-ethyl-N'N'-dimethylaminopropyl
carbodiimide
Et = ethyl
EtOH = ethanol
10 FAB = Fast Atom Bombardment (Mass Spectrascopy)
FDMS = field desorption mass spectrum
HOAt = 1-hydroxy-7-azabenzotriazole
HOBt = 1-hydroxybenzotriazole
HPLC = High Performance Liquid Chromatography
15 HRMS = high resolution mass spectrum
i-PrOH = isopropanol
IR = Infrared Spectrum
L = liter
Me = methyl
20 MeOH = methanol
MPLC = Medium Pressure Liquid Chromatography
Mp = melting point
MTBE = t-butyl methyl ether
NBS = N-bromosuccinimide
25 NMR = Nuclear Magnetic Resonance
Ph = phenyl
p.o. = oral administration
i-Pr = isopropyl
Rochelle's Salt = potassium sodium tartrate
30 SM = starting material
TBS = tert-butyldimethylsilyl
TEA = triethylamine

-27-

Temp. = temperature

TFA = trifluoroacetic acid


THF = tetrahydrofuran

TLC = thin layer chromatography

5


t-BOC = tert-butoxycarbonyl

**Overview Scheme for Preparations
and Examples**



Preparation 1**Synthesis of (1*S*,2*S*,5*R*,6*S*)-2-*tert*-Butoxycarbonylamino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid**

5



A 1 L flask was charged with (1*S*,2*S*,5*R*,6*S*)-2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid monohydrate (24.4 g, 0.12 mol, 1 equiv), dioxane (200 mL) and di-*tert*-butyl dicarbonate (52.4 g, 0.24 mol, 2.0 equiv). The suspension was vigorously stirred while 1*N* sodium hydroxide (420 mL, 3.5 equiv) was added. The mixture was stirred for 2 days, then 2.0 more equiv of di-*tert*-butyl dicarbonate were added and the reaction stirred for 3 additional days at room temperature. After 5 total days of reaction, water (400 mL) was added to dissolve the salts. The aqueous layer was extracted with ethyl acetate (4 x 100 mL) and acidified to pH 2 with 6 *N* hydrochloric acid. The acidic aqueous phase was extracted with ethyl ether (6 x 200 mL). The combined ether extracts were washed with water (250 mL) and brine (250 mL). After drying over sodium sulfate, solvents were evaporated under vacuum to afford a foamy white solid (26.4 g).

77% Yield; mp 100-101 °C.

$[\alpha]_D^{25} = -41.1^\circ$ ($c = 1.0$, MeOH).

-30-

^1H NMR (Methanol- d_4) δ : 4.98 (brs, 1H), 2.44 (dd, 1H, J = 6.2, 2.6 Hz), 2.19-1.92 (m, 4H), 1.62 (t, 1H, J = 2.8 Hz), 1.43 (s, 9H), 1.29 (m, 1H).

^{13}C NMR (Methanol- d_4) δ : 175.6, 175.2, 158.2, 60.1, 34.6,


5 31.9, 28.4, 27.2, 25.6, 20.6.

MS (Electrospray): 285.12.

Preparation 2

Synthesis of (1*S*,2*S*,5*R*,6*S*)-2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid dimethyl ester hydrochloride

10



(1*S*,2*S*,5*R*,6*S*)-2-*tert*-Butoxycarbonylamino-

15 bicyclo[3.1.0]hexane-2,6-dicarboxylic acid (20 g, 0.07 mol, 1.0 equiv) was dissolved in 210 ml of dry dimethylformamide and potassium carbonate (21.3 g, 0.154 mol, 2.2 equiv) was added at 0 °C under nitrogen. After 15 minutes, methyl iodide (17.6 ml, 0.28 mol, 4.0 equiv) was added. The

20 reaction mixture was warmed up slowly and stirred at room temperature for 3h. Water (200 ml) was added and the aqueous phase was extracted with ethyl ether (4 x 75 ml each). The combined organic phase was washed with cold water (4 x 50 ml), and the aqueous phase extracted again with ethyl ether

25 (2 x 50 ml). After drying the organic phase over sodium sulfate and evaporating under vacuum, a foamy solid ((1*S*,2*S*,5*R*,6*S*)-2-*tert*-butoxycarbonylamino-

-31-

bicyclo[3.1.0]hexane-2,6-dicarboxylic acid-2,6-dimethyl ester) was obtained (19.2 g, 87% yield).


This compound was diluted with 150 ml of a saturated solution of hydrogen chloride gas in ethyl acetate and the mixture vigorously stirred for 1 hour (a white precipitate appeared within 15 minutes). The solid was filtered, rinsed with ethyl ether and thoroughly dried under high vacuum. 73% Yield; mp 193-194 °C.

$[\alpha]_D^{25} = + 22.2^\circ$ ($c = 1.0$, MeOH).

^1H NMR (D_2O) δ : 3.86 (s, 3H), 3.67 (s, 3H), 2.31-2.04 (m, 6H), 1.57 (m, 1H).

^{13}C NMR (Methanol- d_4) δ : 171.9, 170.2, 65.6, 52.8, 51.2, 32.4, 29.9, 28.5, 26.2, 20.7.

Alternative Synthesis of (1*S*,2*S*,5*R*,6*S*)-2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid dimethyl ester-hydrochloride



20

Thionyl chloride (807 mL, 11.1 mol) was added to methanol (9.5 L) over a period of 1 h while maintaining the temperature between 2 - 20 °C. The solution was maintained for 30 min, then (1*S*,2*S*,5*R*,6*S*)-2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid monohydrate (1.61 kg, 7.92 mol) was added. The resulting solution was heated to 47 °C and maintained between 47 - 50 °C for 17 h. Approximately 7.3 L of methanol was then removed by vacuum distillation (47 - 50

-32-

°C, 240 - 275 mm Hg). The remaining methanol was removed by azeotropic distillation with t-butyl methyl ether (MTBE) at atmospheric pressure [added MTBE (10 L), removed 8.5 L; added MTBE (10 L), removed 8.5 L; added MTBE (8 L), removed 5.1 L]. During the course of the distillations a white solid began to precipitate from the solution. After completion of the distillations, MTBE (2 L) was added to the resulting slurry, and the slurry was cooled to 22 °C. The solid was filtered, rinsed with MTBE (2 L) and dried under vacuum to afford 1.94 kg (98%) of the title compound as a white solid.

Analysis Calculated for $C_{10}H_{16}NO_4Cl$: C, 48.10; H, 6.46; N, 5.61; Cl, 14.20. Found: C, 47.88; H, 6.25; N, 5.57; Cl, 14.52.

**General Procedure for the coupling reaction of
(1S,2S,5R,6S)-2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic
acid dimethyl ester hydrochloride with N-BOC-(L)-aminoacids.**

The starting dimethyl ester hydrochloride salt (1.0 equiv), the product of Example Preparation 2, was suspended in dry dichloromethane (0.1 M solution) under nitrogen. The corresponding N-BOC-aminoacid (1.5 equiv), N-ethyl-N',N'-dimethylaminopropylcarbodiimide (EDC, 1.5 equiv) and 1-hydroxybenzotriazole (HOBT, 1.5 equiv) were added in one portion, followed by triethyl amine (1.0 equiv) via syringe and, finally, dimethylaminopyridine (DMAP, 0.1 equiv). The reaction mixture was stirred overnight at room temperature, then hydrolyzed by addition of 1N hydrochloric acid (20 ml / mmol) and diluted with methylene chloride (10 ml / mmol). The aqueous layer was extracted with methylene chloride (5


ml / mmol) and the combined organic layers washed twice with
1 N hydrochloric acid (10 ml / mmol), and finally with water
and brine (10 ml / mmol each). After drying over sodium
sulfate and evaporation under vacuum the crude residue was
5 purified by silica gel chromatography using the appropriate
eluent (typically mixtures hexanes/ethyl acetate).

Alternative procedure for the coupling reaction of
(1S,2S,5R,6S)-2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic
10 acid dimethyl ester hydrochloride with N-BOC-aminoacids.

A solution of dicyclohexylcarbodiimide (DCC) (1.1 equiv) in
methylene chloride (4.0 M solution) was added to a mixture
of Preparation 2 (1.0 equiv), triethylamine (1.0 equiv) and
15 N-t-butoxycarbonyl-L-alanine (1.1 equiv) in methylene
chloride (1.0 M solution) over a period of approximately 1.5
h while stirring. The resulting mixture was stirred for 1 -
12 h then filtered. The filter cake (dicyclohexylurea) was
rinsed with methylene chloride, and the filtrate was washed
20 with 0.1 M NaHCO_3 followed by 1.0 N hydrochloric acid. The
organic phase was dried (Na_2SO_4), filtered and concentrated
to afford the title compound as an oil.

Example 1

Synthesis of (1*S*,2*S*,5*R*,6*S*)-2-[(2'*S*)-(2'-*tert*-
Butoxycarbonylamino)-propionyl]amino-bicyclo[3.1.0]hexane-
5 2,6-dicarboxylic acid dimethyl ester



The starting dimethyl ester hydrochloride salt (1.0 equiv),
10 the product of Preparation 2, was suspended in dry
dichloromethane (0.1 M solution) under nitrogen. N-BOC-(L)-
alanine (1.5 equiv), N-ethyl-N',N'-
dimethylaminopropylcarbodiimide (EDC, 1.5 equiv) and 1-
hydroxybenzotriazole (HOBt, 1.5 equiv) were added in one
15 portion, followed by triethyl amine (1.0 equiv) via syringe
and, finally, dimethylaminopyridine (DMAP, 0.1 equiv). The
reaction mixture was stirred overnight at room temperature,
then hydrolyzed by addition of 1N hydrochloric acid (20 ml /
mmol) and diluted with methylene chloride (10 ml / mmol).
20 The aqueous layer was extracted with methylene chloride (5
ml / mmol) and the combined organic layers washed twice with
1 N hydrochloric acid (10 ml / mmol), and finally with water
and brine (10 ml / mmol each). After drying over sodium
sulfate and evaporation under vacuum the crude residue was
25 purified by silica gel chromatography using mixtures of
hexanes/ethyl acetate.

50% Yield. Foamy white solid. mp 51-52 °C.

$[\alpha]_D^{25} = -27.7$ ($c = 0.52$, CHCl_3).

^1H NMR (CDCl_3) δ : 7.28 (brs, 1H), 5.04 (brd, 1H, $J = 7.6$ Hz),
4.16 (m, 1H), 3.74 (s, 3H), 3.66 (s, 3H), 2.49 (dd, 1H, $J =$
5 13.9, 8.3 Hz), 2.42 (dd, 1H, $J = 6.3, 2.8$ Hz), 2.18-1.89 (m,
3H), 1.70 (t, 1H, $J = 2.9$ Hz), 1.45 (s, 9H), 1.33 (d, 3H, J
= 7.0 Hz), 1.19 (m, 1H).

^{13}C NMR (CDCl_3) δ : 172.8, 172.6, 172.6, 155.7, 80.2, 66.3,
52.6, 51.8, 49.5, 34.4, 32.0, 28.2, 28.1, 26.6, 21.1, 17.6.

10


Alternative Synthesis of (1S,2S,5R,6S)-2-[(2'S)-(2'-tert-Butoxycarbonylamino)-propionyl]amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid dimethyl ester

- 15 A solution of dicyclohexylcarbodiimide (DCC) (1.1 equiv) in methylene chloride (4.0 M solution) was added to a mixture of Example Preparation 2 (1.0 equiv), triethylamine (1.0 equiv) and N-t-butoxycarbonyl-L-alanine (1.1 equiv) in methylene chloride (1.0 M solution) over a period of
- 20 approximately 1.5 h while stirring. The resulting mixture was stirred for 1 - 12h then filtered. The filter cake (dicyclohexylurea) was rinsed with methylene chloride, and the filtrate was washed with 0.1 M NaHCO_3 followed by 1.0 N hydrochloric acid. The organic phase was dried (Na_2SO_4),
- 25 filtered and concentrated to afford the title compound as an oil.

Example 2

Synthesis of (1*S*,2*S*,5*R*,6*S*)-2-[(2'*S*)-(2'-tert-butoxycarbonylamino)-propionyl]amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid

5



A solution of 2 M NaOH (5.45 L, 10.9 mol) was added to a solution of (1*S*,2*S*,5*R*,6*S*)-2-[(2'*S*)-(2'-tert-butoxycarbonylamino)-propionyl]amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid dimethyl ester (4.52 mol, crude) in THF (2.8 L). The resulting mixture was stirred at ambient temperature for 3 h then extracted with CH₂Cl₂ (2 x 3 L). Ethyl acetate (5 L) and tetrahydrofuran (3 L) were then added to the aqueous phase. While stirring, concentrated HCl (970 mL) was added to the mixture until the pH = 2. The organic phase was dried (MgSO₄) and filtered. The aqueous phase was then extracted with ethyl acetate (5 L). The organic phase was dried (MgSO₄), filtered and combined with the previous organic phase. The combined organics were concentrated to a soft solid. Ethyl acetate was then added, and the mixture was concentrated to a soft solid. Ethyl acetate (3.5 L) was again added. The mixture was concentrated until a freely flowing suspension was present. Heptane (1.8 L) was then added, and the slurry was stirred at ambient temperature for 15 h. The solid was filtered,

-37-

washed with heptane (3 L) then dried under vacuum to afford the title compound.

Yield 1.36 kg (84%) as an approximate 85:15 mixture of rotamers as a white solid.


5 $[\alpha]_D^{25} - 24.8$ (C1.0, MeOH)

^1H NMR (DMSO- d_6) δ 12.20 (s, 2 H), 8.40 (s, 0.85 H), 8.36 (s, 0.15 H), 6.69 (d, $J = 8.2$ Hz, 0.85 H), 6.33 (br d, 0.15 H), 3.99 (quintet, $J = 7.2$ Hz, 0.85 H), 3.84 (br m, 0.15 H), 2.18-2.13 (m, 2 H), 1.91-1.84 (m, 1 H), 1.82-1.75 (m, 2 H),
10 1.46 (br s, 0.85 H), 1.43 (br s, 0.15 H), 1.35 (s, 9 H), 1.23-1.15 (m, 1 H), 1.13 (d, $J = 6.9$ Hz, 3 H).

^{13}C NMR (CD_3OD) δ 176.4, 176.0 (2 C), 157.5, 80.5, 67.3 (minor rotamer), 67.2 (major rotamer), 50.9, 35.6, 32.8, 29.3, 28.7, 27.4, 22.1, 18.5.

15 MS (EI) calcd for $\text{C}_{16}\text{H}_{28}\text{N}_3\text{O}_7$ ($\text{M} + \text{NH}_4^+$) 374.20, found 374.24 m/z .

Alternative Synthesis of (1*S*,2*S*,5*R*,6*S*)-2-[(2'*S*)-(2'-*tert*-
Butoxycarbonylamino)-propionyl]amino-bicyclo[3.1.0]hexane-
20 2,6-dicarboxylic acid



A solution of (1*S*,2*S*,5*R*,6*S*)-2-amino-
25 bicyclo[3.1.0]hexane-2,6-dicarboxylic acid monohydrate (85 g, 418 mmol) and MeOH (850 mL) was cooled to 10 °C. Thionyl

-38-

chloride (199 g, 1.67 mol) was added at a rate such that the temperature did not exceed 20 °C. The solution was then heated to 50 °C and stirred for 6 h. Upon completion of the reaction, the solution was cooled to room temperature and concentrated to approximately 170 mL total volume under reduced pressure at 20 - 30 °C. Water (850 mL) was added, and the pH of the solution was adjusted to approximately pH 2.0 with 1.0 N NaOH (300 mL). The solution was concentrated under reduced pressure until the temperature reached approximately 40 °C. Methylene chloride (850 mL) was then added, and the pH of the solution was adjusted to pH 8 with 1.0 N NaOH (180 mL). The phases were separated, and the aqueous phase was extracted with CH₂Cl₂ (425 mL). The combined organic phases containing the corresponding dimethyl ester were concentrated to approximately 425 mL total volume and held for further processing.


In a separate reaction vessel a solution of N-t-butoxycarbonyl-L-alanine (83.2 g, 439 mmol) and 4-methylmorpholine (44.4 g, 439 mmol) in CH₂Cl₂ (712 mL) was cooled to -5 - -10 °C. Isobutyl chloroformate (59.9 g, 439 mmol) was then added at rate such that the temperature did not exceed -5 °C. Upon completion of the addition, the solution was stirred for 15 min. Simultaneously, CH₂Cl₂ (20 mL) was added to the dimethyl ester solution previously prepared, and this solution was cooled to -5 °C. The dimethyl ester solution (445 mL) was then added to the isobutyl mixed anhydride mixture. The cooling bath was removed, and the corresponding mixture was stirred for 30 min. A solution of 1.0 N HCl (445 mL) was then added. The phases were separated, and the organic phase was washed with 1.0 N HCl (445 mL). The organic phase was concentrated to approximately 180 mL total volume. THF (450 mL) was then

-39-

added, and the resulting solution was concentrated to approximately 180 mL total volume. To this solution was added 1.0 N NaOH (1.67 L, 1.67 mol). The resulting mixture was heated to 40 °C, stirred for 1.5 h then cooled to room temperature. Ethyl acetate (2.4 L) was added, and the pH of the aqueous phase was adjusted to pH 2.1 with concentrated HCl (150 mL). The phases were separated, and the aqueous phase was extracted with ethyl acetate (800 mL). The combined organic phases were dried with MgSO₄, filtered and washed with EtOAc (2 x 320 mL). The resulting solution was then concentrated to approximately 400 mL total volume. Ethyl acetate (800 mL) was added, and the solution was concentrated to 400 mL). This ethyl acetate addition/concentration was repeated again, then heptane (640 mL) was added. The resulting mixture was stirred for 2 h, filtered and washed with a 2 : 1 mixture of heptane-ethyl acetate (2 x 320 mL) to afford 115.5 g (78% yield) of (1*S*,2*S*,5*R*,6*S*)-2-[(2'*S*)-(2'-*tert*-butoxycarbonylamino)-propionyl]amino-bicyclo[3.1.0] hexane-2,6-dicarboxylic acid as a white solid.

Example 3

Synthesis of (1*S*,2*S*,5*R*,6*S*)-2-[(2'*S*)-(2'-Amino)-propionyl]amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid hydrochloride




-40-

- To a solution of ethyl acetate (500 mL) was added HCl (79.0 g, 2.16 mol). The resulting HCl solution was then added to a slurry of (1*S*,2*S*,5*R*,6*S*)-2-[(2'*S*)-(2'-tert-butoxycarbonylamino)-propionyl]amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid (100 g, 281 mmol) in ethyl acetate (500 mL) at a rate such that the temperature did not exceed 25 °C. The resulting mixture was stirred for 3.5 hours then filtered affording 82.6 g of (1*S*,2*S*,5*R*,6*S*)-2-[(2'*S*)-(2'-Amino)-propionyl]amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid hydrochloride as an amorphous, white solid. This white solid was then added to acetone (290 mL) and water (57 mL). The resulting mixture was heated to 48 - 52 °C, and water (6.4 mL) was added until all of the solid dissolved. Acetone (2.2 L) was added to the resulting solution over a period of approximately 1 h. When the addition of acetone began, the heating mantle was removed. After the addition was complete, the mixture was cooled to 0 - -10 °C and stirred for 4 h. The mixture was then filtered and washed with cold acetone (75 mL) affording (1*S*,2*S*,5*R*,6*S*)-2-[(2'*S*)-(2'-amino)-propionyl]amino-bicyclo[3.1.0] hexane-2,6-dicarboxylic acid hydrochloride that was dried under vacuum at 40 °C to provide 76.6 g (93% yield) of the title compound as a white, crystalline solid.
- 72% Yield. White crystalline solid. mp >250 °C, dec.
- [α]_D²⁵ = - 7.80 (c = 1.0, MeOH).
- ¹H NMR (Methanol-*d*₄) δ : 3.96 (q, 1H, *J* = 7.0 Hz), 2.47 (dd, 1H, *J* = 6.3, 2.7 Hz), 2.37 (dd, 1H, *J* = 13.6, 8.2 Hz), 2.18-1.92 (m, 3H), 1.66 (t, 1H, *J* = 3.0 Hz), 1.53 (d, 3H, *J* = 7.0 Hz), 1.46-1.34 (m, 1H).
- ¹³C NMR (Methanol-*d*₄) δ : 175.2, 174.7, 170.2, 66.4, 49.0, 36.6, 32.0, 28.5, 26.3, 21.2, 16.6.

80% Yield. White solid.

Example 4

Synthesis of (1*S*,2*S*,5*R*,6*S*)-2-[(2'*S*)-(2'-Amino)-
5 propionyl]amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid
methanesulfonate



10

A solution of (1*S*,2*S*,5*R*,6*S*)-2-[(2'*S*)-(2'-tert-butoxycarbonylamino)-propionyl]amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid (1.07 g, 3.00 mmol), methanesulfonic acid (584 μ L, 9.00 mmol) and dioxane (10 mL) was stirred for
15 48 h. The mixture was filtered and dried to afford (1*S*, 2*S*, 5*R*, 6*S*)-2-[(2'*S*)-(2'-Amino)-propionyl]amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid methane sulfonate as a crude, white, amorphous solid (1.05 g). A sample of this solid (1.0 g) was dissolved in MeOH (10 mL). The
20 solution was concentrated to 3.3 g total weight and seed crystals were added. Ethyl acetate (10 mL) was then added to the mixture over a period of 15 min. The mixture was stirred for 30 min, filtered and dried under vacuum to afford 830 mg of the title compound as a white, crystalline
25 solid.

Yield 78%

-42-

^1H NMR (CD_3OD) δ 3.96 (q, J = 7.1 Hz, 1 H), 2.71 (s, 3 H),
2.45 (dd, J = 6.4, 2.7 Hz, 1 H), 2.38 (dd, J = 13.9, 8.4 Hz,
1 H), 2.20-2.08 (m, 1 H), 2.01-1.93 (m, 2 H), 1.67 (t, J =
2.9 Hz, 1 H), 1.52 (d, J = 7.0 Hz, 3 H), 1.46-1.35 (m, 1 H)

5 ^{13}C NMR (CD_3OD) δ 176.3, 175.7, 171.2, 67.4, 50.0, 39.5,
35.7, 33.1, 29.5, 27.4, 22.2, 17.6.


Anal. Calcd for $\text{C}_{12}\text{H}_{20}\text{N}_2\text{O}_8\text{S}$: C, 40.90; H, 5.72; N, 7.95.

Found: C, 40.81; H, 5.69; N, 7.83.

10

Example 5

Synthesis of (1*S*,2*S*,5*R*,6*S*)-2-[(2'*S*)-(2'-Amino)-
propionyl]amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid



15 (1*S*, 2*S*, 5*R*, 6*S*)-2-[(2'*S*)-(2'-Amino)- propionyl]amino-
bicyclo[3.1.0]hexane-2,6-dicarboxylic acid hydrochloride
(1.0 g, 3.42 mmol) was dissolved in water (1 mL), and 1.0 N
NaOH (3.42 mL, 3.42 mmol) was added. The solution was
maintained in the refrigerator for 24 h. The solution
20 remained clear. Acetone (2 mL) was added, and the solution
was stored in the refrigerator for 16 h. A white solid
precipitated out of solution, and mixture could not be
stirred. Acetone (4 mL) was added, and the mixture was
stirred at rt, then filtered and dried to afford 630 mg of
25 the title compound as a white crystalline solid which
contained 2-4% NaCl.

-43-


Yield 72%

^1H NMR (CD_3OD) δ 3.93 (q, $J = 7.1$ Hz, 1 H), 2.48 (dd, , $J =$
6.6, 2.9 Hz, 1 H), 2.32 (dd, , $J = 13.5, 8.4$ Hz, 1 H), 2.20-
2.08 (m, 1 H), 2.01-1.90 (m, 2 H), 1.61 (t, , $J = 2.9$ Hz, 1
5 H), 1.51 (d, , $J = 7.0$ Hz, 3 H), 1.48-1.33 (m, 1 H) ^{13}C NMR
(CD_3OD) δ 176.9 (2 C), 171.1, 68.0, 50.1, 35.9, 33.2, 29.7,
27.3, 22.5, 17.6.

-44-

CLAIMS

1. A compound of formula I



5

wherein

R¹³, R¹⁴ and R¹⁷ are hydrogen;

or a pharmaceutically acceptable salt thereof.

10

2. A pharmaceutically acceptable salt of a compound of formula I as claimed Claim 1 which is an acid-addition salt made with an acid which provides a pharmaceutically acceptable anion or, for a compound which contains an acidic moiety, which is a salt made with a base which provides a pharmaceutically acceptable anion.


3. The pharmaceutically acceptable salt of a compound of formula I as claimed in Claim 2 which is (1*S*,2*S*,5*R*,6*S*)-2-[(2'*S*)-(2'-Amino)-propionyl]amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid hydrochloride salt.

4. The pharmaceutically acceptable salt of a compound of formula I as claimed in Claim 2 which is (1*S*,2*S*,5*R*,6*S*)-2-[(2'*S*)-(2'-Amino)-propionyl]amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid methane sulfonate salt.

5. A pharmaceutical formulation comprising in association with a pharmaceutically acceptable carrier, diluent or excipient, a compound of formula I (or a pharmaceutically acceptable salt thereof) as provided in any one of Claims 1 to 4.

6. A process for preparing the compound of formula I, or a pharmaceutically acceptable salt thereof, as claimed in any one of Claims 1 to 4 comprising:

10 for a compound of formula I, deprotecting a compound of formula IV



IV

where R^m is a nitrogen protecting group; and
15 R^{13} and R^{14} are carboxy protecting groups;

whereafter, for any of the above procedures, when a functional group is protected using a protecting group, removing the protecting group;

whereafter, for any of the above procedures, when a
20 pharmaceutically acceptable salt of a compound of formula I is required, it is obtained by reacting the basic form of such a compound of formula I with an acid affording a physiologically acceptable counterion, or, for a compound of formula I which bears an acidic moiety, reacting the acidic
25 form of such a compound of formula I with a base which affords a pharmaceutically acceptable cation, or by any other conventional procedure.

7. A method for affecting the cAMP-linked metabotropic glutamate receptors in a patient, which comprises administering to a patient requiring
5 modulated excitatory amino acid neurotransmission a pharmaceutically-effective amount of a compound of any one of Claims 1 to 4.

8. A method of administering an effective amount
10 of a compound of formula II, where R^{13} and R^{14} are both hydrogen (a di-acid), which comprises administering to a patient requiring modulated excitatory amino acid neurotransmission a pharmaceutically effective amount
of a compound of any one of Claims 1 to 4.

15

9. A method for treating a neurological disorder in a patient which comprises administering to the patient in need of treatment thereof a pharmaceutically-effective amount of a compound of any
20 one of Claims 1 to 4.

10. The method of Claim 9 wherein said neurological disorder is cerebral deficits subsequent to cardiac bypass and grafting; cerebral ischemia;
25 spinal cord trauma; head trauma; Alzheimer's Disease; Huntington's Chorea; amyotrophic lateral sclerosis; AIDS-induced dementia; perinatal hypoxia; hypoglycemic neuronal damage; ocular damage and retinopathy; cognitive disorders; idiopathic and drug-induced
30 Parkinson's Disease; muscular spasms; migraine headaches; urinary incontinence; drug tolerance, withdrawal, and cessation; smoking cessation; emesis;

-47-

brain edema; chronic pain; sleep disorders;
convulsions; Tourette's syndrome; attention deficit
disorder or tardive dyskinesia.


5 11. The method of Claim 10 wherein said
neurological disorder is drug tolerance, withdrawal,
and cessation or smoking cessation.

10 12. A method for treating a psychiatric disorder
in a patient which comprises administering to the
patient in need of treatment thereof a
pharmaceutically-effective amount of a compound of any
one of Claims 1 to 4.

15 13. The method of Claim 12 wherein said
psychiatric disorder is schizophrenia, anxiety and
related disorders, depression, bipolar disorders,
psychosis or obsessive compulsive disorders.

20 14. The method of Claim 13 wherein said
psychiatric disorder is anxiety and related disorders.

25 15. A compound of formula IV



wherein R^m is a nitrogen protecting group;
 R^{11} is CO_2R^{14} and R^{12} is hydrogen or fluoro; or R^{11} is
hydrogen or fluoro and R^{12} is CO_2R^{14} ; and
5 R^{13} and R^{14} are carboxy protecting groups.

16. A compound of formula IV as claimed in Claim 21
wherein R^m is tert-butoxycarbonyl, R^{11} is CO_2R^{14} ; R^{13} and R^{14}
are both methyl; and R^{12} is hydrogen.

10

17. A compound of formula I, or a pharmaceutically
acceptable salt thereof, as claimed in any one of Claims 1
to 4 for use as a pharmaceutical.

15

18. Use of a compound of formula I, or a
pharmaceutically acceptable salt thereof, for the
manufacture of a medicament for treating neurological or
psychiatric disorders.

20

19. A novel compound of formula I substantially as
hereinbefore described with reference to any of the
Examples.

20. A method for affecting the CAMP-linked
25 metabotropic glutamate receptors in a mammal, which
comprises administering to a mammal requiring modulated
excitatory amino acid neurotransmission a pharmaceutically
effective amount of a compound of formula I substantially as
hereinbefore described with reference to any of the
30 Examples.

21. A process for preparing a novel compound of formula I substantially as hereinbefore described with reference to any of the Examples.

INTERNATIONAL SEARCH REPORT

Int lonal Application No
PCT/US/45866

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07C229/50 C07C233/60 A61K31/195 A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 696 577 A (LILLY CO ELI) 14 February 1996 (1996-02-14) cited in the application the whole document	1
A	EP 1 052 246 A (TAISHO PHARMA CO LTD) 15 November 2000 (2000-11-15) claims 1-8	1
X	WO 00 04010 A (LILLY SA ;DOMINGUEZ FERNANDEZ CARMEN (ES); EZQUERRA CARRERA JESUS) 27 January 2000 (2000-01-27) example 9	15



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

19 April 2002

Date of mailing of the international search report

03/05/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Goetz, G

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US96/45866

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0696577	A	14-02-1996	US 5750566 A 12-05-1998
			AP 758 A 10-09-1999
			AT 172186 T 15-10-1998
			AT 206915 T 15-11-2001
			AU 692276 B2 04-06-1998
			AU 2853095 A 22-02-1996
			AU 3325095 A 07-03-1996
			AU 3325195 A 07-03-1996
			AU 3364995 A 07-03-1996
			BG 62728 B1 30-06-2000
			BG 101213 A 31-03-1998
			BR 9503638 A 28-05-1996
			CA 2156024 A1 13-02-1996
			CA 2195779 A1 22-02-1996
			CA 2195782 A1 22-02-1996
			CN 1123272 A ,B 29-05-1996
			CZ 9502074 A3 15-05-1996
			DE 69505318 D1 19-11-1998
			DE 69523324 D1 22-11-2001
			DK 696577 T3 23-06-1999
			DK 776201 T3 26-11-2001
			EP 0696577 A1 14-02-1996
			EP 0776200 A1 04-06-1997
			EP 0776201 A1 04-06-1997
			ES 2122456 T3 16-12-1998
			ES 2162936 T3 16-01-2002
			FI 953837 A 13-02-1996
			HK 1013983 A1 14-07-2000
			HU 75524 A2 28-05-1997
			IL 114910 A 29-06-2000
			JP 2883297 B2 19-04-1999
			JP 8188561 A 23-07-1996
			JP 10504038 T 14-04-1998
			JP 11507008 T 22-06-1999
			NO 953191 A 13-02-1996
			NZ 272772 A 24-10-1997
			PL 309972 A1 19-02-1996
			RU 2152925 C1 20-07-2000
			SI 696577 T1 30-04-1999
			SK 13397 A3 09-07-1997
			TW 438741 B 07-06-2001
			WO 9604900 A1 22-02-1996
			WO 9604901 A1 22-02-1996
			WO 9605175 A1 22-02-1996
			US 5661184 A 26-08-1997
			US 5882671 A 16-03-1999
			US 5925782 A 20-07-1999
			US 5925680 A 20-07-1999
EP 1052246	A	15-11-2000	AU 734812 B2 21-06-2001
			AU 2183599 A 16-08-1999
			CA 2318800 A1 25-08-1999
			EP 1052246 A1 15-11-2000
			US 6316498 B1 13-11-2001
			CN 1295557 T 16-05-2001
			JP 11279129 A 12-10-1999
			WO 9938839 A1 05-08-1999

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 45866

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0004010 A	27-01-2000	AU 4922399 A	07-02-2000
		EP 1097149 A1	09-05-2001
		WO 0004010 A1	27-01-2000

Form PCT/ISA/210 (patent family annex) (July 1992)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 July 2002 (18.07.2002)

PCT

(10) International Publication Number
WO 02/055481 A1

(51) International Patent Classification⁷: C07C 229/50,
233/60, A61K 31/195, A61P 25/00

LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK (utility model), SK, SL, TJ, TM, TR, TT, TZ, UA,
UG, US, UZ, VN, YU, ZA, ZW.

(21) International Application Number: PCT/US01/45866

(22) International Filing Date:
21 December 2001 (21.12.2001)

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
01500007.8 11 January 2001 (11.01.2001) EP
01500206.6 2 August 2001 (02.08.2001) EP
60/329,786 16 October 2001 (16.10.2001) US
01500263.7 7 November 2001 (07.11.2001) EP

Declaration under Rule 4.17:

— as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE,
SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL,
SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG,
KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG)

(71) Applicant (for all designated States except US): ELI
LILLY AND COMPANY [US/US]; Lilly Corporate
Center, Indianapolis, IN 46285 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): COFFEY, David,
Scott [US/US]; 6246 Tannison Way, Indianapolis, IN
46236 (US). MONN, James, Allen [US/US]; 5718
Allenwood Court, Indianapolis, IN 46268 (US). PED-
ERSEN, Steven, Wayne [US/US]; 3724 Ontario Circle,
Indianapolis, IN 46268 (US). PEDREGAL-TERCERO,
Concepcion [ES/ES]; Lilly, S. A., Avenida de la Industria
30, E-28100 Alcobendas (ES).

Published:

— with international search report

(74) Agents: ANDERSON, Arvie, J. et al.; Eli Lilly and Com-
pany, Lilly Corporate Center, Indianapolis, IN 46285 (US).

(48) Date of publication of this corrected version:
2 October 2003

(81) Designated States (national): AE, AG, AL, AM, AT (uti-
lity model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (uti-
lity model), DE, DK (utility model), DK, DM, DZ, EC, EE
(utility model), EE, ES, FI (utility model), FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,

(15) Information about Correction:
see PCT Gazette No. 40/2003 of 2 October 2003, Section II

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PRODRUGS OF EXCITATORY AMINO ACIDS

(57) Abstract: This invention relates to synthetic excitatory amino acid prodrugs according to formula (I) and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.

WO 02/055481 A1

This Page Blank (uspto)